The structure-function relationship of oncogenic LMTK3

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Lemur tyrosine kinase 3 (LMTK3) signaling is implicated in cancer progression.
• Understanding LMTK3's role is vital for developing targeted cancer therapies.

Purpose of the Study:

• To elucidate the structure and function of LMTK3.
• To identify and characterize a novel small-molecule inhibitor of LMTK3.
• To evaluate the therapeutic potential of LMTK3 inhibition in preclinical cancer models.

Main Methods:

• X-ray crystallography to determine LMTK3 kinase domain structure.
• Phosphoproteomic analysis to identify LMTK3 substrates.
• High-throughput screening for LMTK3 inhibitors.
• Biochemical, cellular, and biophysical assays.
• In vivo studies using xenograft and transgenic mouse models.

Main Results:

• The crystal structure of LMTK3 kinase domain was solved to 2.1Å resolution.
• A potent LMTK3 inhibitor, C28, was identified, which promotes proteasome-mediated degradation of LMTK3.
• LMTK3 was found to be a heat shock protein 90 (HSP90) client protein.
• Pharmacologic inhibition of LMTK3 reduced cancer cell proliferation and increased apoptosis in breast cancer cells.
• LMTK3 inhibition demonstrated efficacy in preclinical breast cancer models with no systemic toxicity.

Conclusions:

• LMTK3 is a druggable target for cancer therapy.
• The small-molecule inhibitor C28 effectively targets LMTK3, leading to cancer cell death.
• Targeting LMTK3 represents a promising strategy for developing novel anti-cancer drugs.